Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., has been appointed President and Chief Executive Officer (CEO) with effect from February 1, 2020.
Get the latest stock price information, including historical values and our investment calculator.